candidemia – mycolab.ai

Closing the diagnostic gap in medical mycology: The LODDY Test for identification of Lodderomyces elongisporus

mycolabadmin

Researchers developed a simple and affordable test called the LODDY Test to identify a dangerous yeast called Lodderomyces elongisporus that is often mistaken for a similar but less dangerous yeast. This test uses color changes on a special culture medium to distinguish between different yeast species in just 48 hours without expensive equipment. The test works perfectly in laboratories worldwide and could help doctors in developing countries diagnose and treat serious fungal infections more quickly and accurately.

Candida blankii: The Difficult Capture of a Fungus With Pathogenic Potential

mycolabadmin

Candida blankii is a rare fungal pathogen that is increasingly being found in hospital patients’ bloodstreams and respiratory tracts. The organism is difficult to identify using standard laboratory tests, which can delay diagnosis and treatment. This case report describes two adult patients with C. blankii infections and highlights the challenges in identifying this emerging pathogen and its resistance to common antifungal medications.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading expert in fungal infections, shares his 48 years of experience studying infectious diseases, particularly focusing on Cryptococcus and candida infections. He discusses how antifungal medications have evolved from highly toxic drugs to more effective treatments, while emphasizing the need for faster-acting drugs that require shorter treatment periods. The interview covers emerging diagnostic tools using molecular methods, the promise of combining drugs with immune-boosting therapies, and the importance of understanding how fungi survive in the human body to develop better treatments.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect shares decades of experience treating fungal infections and developing antifungal medications. He discusses how treatments have evolved from highly toxic drugs to more effective options, but notes that fungal infections remain challenging, especially when patients develop resistance or have serious underlying diseases. He emphasizes the importance of combining drugs with immune therapies and shorter, more potent treatments rather than lengthy medication courses. Despite challenges, Dr. Perfect is optimistic about the future of medicine and encourages young scientists to pursue careers in this field.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading infectious disease expert, discusses his 48-year career studying fungal infections, particularly cryptococcal meningitis. He reflects on the dramatic transformation of HIV/AIDS from a fatal disease to a manageable chronic condition and emphasizes that antifungal resistance is less concerning than the underlying diseases that complicate treatment. Perfect advocates for developing more potent antifungal drugs that work faster, and discusses promising approaches like molecular diagnostics and immune-based therapies to improve patient outcomes.

Candidemia due to Candida lambica in a neutropenic oncology patient: A rare case report

mycolabadmin

A 56-year-old cancer patient developed a serious bloodstream infection caused by a rare yeast called Candida lambica despite taking antifungal medications. Doctors identified the infection using genetic sequencing and found that the organism was sensitive to a different antifungal drug called voriconazole. After switching medications and removing the patient’s central line, the infection cleared up. This case demonstrates the importance of accurately identifying fungal infections and testing which medications work best against them.

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005–2025)

mycolabadmin

Invasive candidiasis, a serious fungal blood infection caused by Candida species, is a major health crisis in Latin America and the Caribbean with death rates reaching 60% in vulnerable populations. The disease is worsening in areas affected by armed conflict, violence, and displacement where poor living conditions, overcrowding, malnutrition, and lack of healthcare create ideal conditions for the infection to develop and spread. Antifungal drugs are often unavailable or too expensive, and drug-resistant strains of Candida are becoming increasingly common, making treatment extremely challenging in these regions.

Persistent Candidemia: Predictors and Outcomes in a Multicenter Matched Analysis

mycolabadmin

This study examined cases where fungal infections caused by Candida persisted in the bloodstream even after starting antifungal treatment. Researchers compared 46 patients with persistent infections to 92 control patients without persistent infections across three major medical centers. Patients with persistent candidemia were younger, more likely to be female, had more health complications, and sadly had much higher death rates (54% vs 31%) within 90 days. The findings suggest that certain patient characteristics and fungal species types may help identify those at higher risk of persistent infections.

Candidemia due to Candida lambica in a neutropenic oncology patient: A rare case report

mycolabadmin

A 56-year-old cancer patient developed a rare blood infection caused by an unusual yeast called Candida lambica while receiving chemotherapy. Despite taking antifungal medication for prevention, the patient developed a serious fever and low white blood cell count. Doctors identified the infection through genetic testing and treated it with a different antifungal drug called voriconazole, which successfully cleared the infection.

Research Topic: candidemia